These 6 Drugs Could Lose Medicare Part D Coverage in 2027

Medicare Part D plans review their drug lists every year, and 2027 may bring more changes than usual as insurers keep adjusting to Inflation Reduction Act reforms. Some people could pay less. Others could face narrower lists, higher cost tiers, or new approval rules. Six groups of medications are expected to get extra attention from plans. They range from costly specialty treatments to popular diabetes and weight loss drugs. Is yours one of them? Let’s start with the group that tends to carry the biggest price tags.

This article was created with the assistance of AI and reviewed by our editorial team for accuracy and clarity.

Drug Group 1: Specialty Medications Face Closer Scrutiny

Specialty drugs are among the most expensive medications Part D covers. They are often prescribed for conditions like multiple sclerosis, rheumatoid arthritis, and cancer. Because the costs are so high, plans may watch this spending more closely. That could mean a change in the drug’s tier, or a new requirement for prior authorization, which means the plan must approve the drug before it pays. If you take a specialty medication, check your plan’s 2027 paperwork early. A small change in how it is covered can have a big effect on your budget. Next up, drugs with no cheaper copy.

Drug Group 2: Brand Name Drugs Without Generics

Some medications have no generic version, which leaves patients without a lower-cost option. These prescriptions can cost far more than generics, so they are often a focus when plans try to control spending. A drug might stay covered but move to a higher tier. In everyday terms, that can mean a bigger copay or a larger share of the bill. That is why it pays to find each of your prescriptions on your plan’s 2027 drug list instead of assuming the cost will stay the same. Some of these drugs also belong to our next group.

Drug Group 3: Biologics Made From Living Organisms

Biologics are made from living organisms instead of being mixed from chemicals in a lab. They are commonly used for autoimmune diseases, certain cancers, and inflammatory conditions. Because they are often expensive, they tend to make up a sizable share of prescription spending. Plans may take another look at how they cover biologics, including where they sit on the drug list and how much members pay. If you take one, review your 2027 plan materials for changes to its tier, its coverage rules, or any preferred alternatives. Speaking of alternatives, the next group works a little differently.

Drug Group 4: Medications With Cheaper Alternatives

When several treatments exist for the same condition, Medicare plans often nudge patients toward the lower-cost option. One tool is step therapy. Under these rules, you may need to try a less expensive drug first before the plan approves a pricier one. That does not necessarily mean your medication is no longer covered. It means getting coverage could involve extra steps that were not required before. If your doctor prescribes a drug that has a cheaper alternative, ask whether your plan uses this rule. A quick call to your insurer now could save weeks of delays later.

Drug Group 5: Weight Loss Medications Stay in the Spotlight

Weight loss drugs remain one of the most closely watched categories in prescription coverage. Medicare has historically restricted coverage for medications prescribed only for weight loss, though some may qualify when used to treat other approved conditions. Coverage can vary by plan and by the reason a drug is prescribed, so your own plan’s details matter. If you or a loved one takes one of these medications, read the 2027 plan documents carefully. And there is another development involving some of the best-known diabetes and obesity drugs that you will want to see next.

Drug Group 6: Medications Tied to Price Negotiations

On Jan. 1, 2027, Medicare’s negotiated prices begin for a second group of 15 Part D drugs. The list includes treatments for diabetes, asthma, COPD, prostate cancer, and breast cancer. Ozempic and Wegovy are among them. These prices are meant to lower what Medicare pays, and they could reduce costs for some people too. But a negotiated price does not guarantee every plan will cover a drug the same way. Plans still set their own drug lists, tiers, and approval rules within Medicare’s guidelines. Check your plan before assuming your costs will drop.

Why a New $2,400 Spending Cap Matters for All Six

Whichever group your medication falls into, the yearly out-of-pocket limit affects you. In 2026, that limit is $2,100. In 2027, it rises to $2,400. Once you reach it, you pay nothing for covered Part D drugs for the rest of the year. The maximum deductible also increases, from $615 to $700, depending on your plan. People with very high drug costs get strong protection, but plans may still manage spending through drug lists and approval rules. If you take several expensive medications, reviewing your plan matters even more. Now for the best time to do that.

Open Enrollment Is Your Window to Compare Plans

Medicare open enrollment runs from Oct. 15 to Dec. 7 each year. This is your chance to compare plans instead of letting your current coverage renew on autopilot. Each fall, your plan sends an Annual Notice of Change explaining what will be different in January. Plans must notify members when a covered drug is removed or moved to a different tier, so that letter deserves a careful read. A medication that was affordable this year could land on a higher tier, and one that needed no approval could suddenly require paperwork. Here is a simple checklist to put it all together.

Your Checklist for Protecting Your Prescriptions

Before choosing a 2027 plan, search every prescription you take using Medicare’s Plan Finder. Review the updated drug list and look for new prior authorization or step therapy rules. Compare total yearly drug costs, not just monthly premiums, since a low premium can hide high drug costs. If a medication appears to have changed status, contact your insurer. A local SHIP counselor can also offer free Medicare guidance. The big takeaway: Part D coverage is never set in stone, and a few minutes of review could help you avoid unexpected costs.